<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01947439</url>
  </required_header>
  <id_info>
    <org_study_id>BATTLE IN MULTI</org_study_id>
    <nct_id>NCT01947439</nct_id>
  </id_info>
  <brief_title>Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI</brief_title>
  <official_title>Prospective,Multicenter Study of Randomized Comparison of the Biolimus A9-eluting Stent With the Zotarolimus-eluting Stent in Multi-vessel PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The risk of restenosis in the treatment of coronary artery disease has significantly lessened
      thanks to the introduction of Drug eluting stent.

      Yet, debates on the efficacy and safety of stents in complex lesions or patients have been
      circulated.

      Recently, PCI in multiple lesions is universally performed with the development of effective
      stents in various kinds in the clinics.

      However, a randomized study is rare for multi-vessel coronary artery disease in real
      procedural environments.

      The primary purpose of this study is to evaluate the clinical progress of biolimus A9-eluting
      stent and zotarolimus-eluting stent in multi-vessel coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients who need multi-vessel stenting with multi-vessel coronary artery disease will be
      enrolled.Each randomization of the enrolled subjects will be done 1:1 (biolimus A9-eluting
      stent : zotarolimus-eluting stent). Randomization will be stratified by two factors: Diabetes
      mellitus and Acute coronary syndrome.Clinical follow-up will occur at the following time
      points; 1 month, 1 year and 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2-year composite end points</measure>
    <time_frame>up to 2 years</time_frame>
    <description>All cause death, non fatal myocardial infarction, any revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>up to 2 years</time_frame>
    <description>All cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-cardiac death</measure>
    <time_frame>up to 2 years</time_frame>
    <description>non-cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>up to 2 years</time_frame>
    <description>cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non fatal myocardial infarction</measure>
    <time_frame>up to 2 years</time_frame>
    <description>non fatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any revascularization</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>up to 2 years</time_frame>
    <description>stent thrombosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">932</enrollment>
  <condition>Multivessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Biolimus A9 eluting stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>biolimus A9 stent( Biomatrix or Biomatrix Flex) will be placed in under Percutaneous Coronary Intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zotarolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>zotarolimus eluting stent (Resolute Integrity) will be placed in under Percutaneous Coronary Intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Coronary Intervention</intervention_name>
    <description>Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent</description>
    <arm_group_label>Biolimus A9 eluting stent</arm_group_label>
    <arm_group_label>Zotarolimus-eluting stent</arm_group_label>
    <other_name>-Resolute Integrity</other_name>
    <other_name>-Biomatrix</other_name>
    <other_name>-Biomatrix Flex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients who need multi-vessel stenting with multi-vessel disease

          -  patients with signed informed consent

        Exclusion Criteria:

          -  known contraindication to any of the following medications: Aspirin,clopidogrel,
             heparin, contrast agent, Biolimus or Zotarolimus group

          -  Cardiogenic shock

          -  Pregnant women or women with potential childbearing

          -  End-stage diseases with life expectancy shorter than 2 years

          -  patients with other Drug eluting stents implanted

          -  Patients requiring modification of antiplatelet agents for planned major surgery
             within the first 12 months after the enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chang-Wook Nam, Postdoctoral</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chang-Wook Nam, Postdoctoral</last_name>
    <phone>82-53-250-8015</phone>
    <email>namcwcv@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Kwangju</city>
        <state>Chonnam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Young-Joon Hong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <state>Gyeongbuk</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eun-Seok Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Ilsan</city>
        <state>Kyeongki</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joon-Hyung Doh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kosin University Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jung-Ho Heo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jin-Bae Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Daegu Fatima Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bong-Ryeol Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KyungPook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jang-Hoon Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Woong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bon-Kwon Koo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2013</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Keimyung University Dongsan Medical Center</investigator_affiliation>
    <investigator_full_name>NAM, Chang-Wook</investigator_full_name>
    <investigator_title>Associate Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>multivessel stenting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Umirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

